In the third sensitivity analysis, excluding patients using other types of glucagon-like peptide-1 receptor agonists, the use of once-weekly semaglutide still independently predicted a higher risk of upcoming NAION (multivariable adjusted HR 234, 95% CI 154 357), compared to non-semaglutide users in a multivariable model adjusted as in the first sensitivity analysis
The 3.0 mL dilution keeps every dose at 18 units or more for accurate measuring
Researchers looked at the impact of bariatric surgery on more than five dozen health outcomes, and although people who underwent surgery may be more likely to kill themselves, break bones, and suffer acid reflux, they also appear to get less diabetes, high blood pressure, and high cholesterol, and less cancer and cardiovascular disease

Patient Assessment Protocol Comprehensive medical history with obesity-specific screening Physical examination including BMI, waist circumference, and body composition analysis Laboratory workup: complete metabolic panel, lipid panel, HbA1c, thyroid function, insulin levels Screening for sleep apnea, PCOS, Cushing syndrome, and other secondary causes of obesity Mental health screening for binge eating disorder and depression Readiness-to-change assessment Medication Formulary for Your Medical Weight Loss Program GLP-1 receptor agonists: Semaglutide (Wegovy), liraglutide (Saxenda), tirzepatide (Zepbound) Sympathomimetic agents: Phentermine (short-term), phentermine/topiramate (Qsymia) Other FDA-approved options: Naltrexone/bupropion (Contrave), orlistat (Xenical/Alli) Off-label considerations: Metformin, topiramate, bupropion (when clinically appropriate and properly documented) Your medical weight loss program's protocols should specify prescribing criteria, dosing escalation schedules, monitoring requirements, and discontinuation criteria for each medication

Pick one lead peptide, one supporting hydrator, and one texture direction